MUC1-C overexpression has been associated with the progression of pancreatic tumors by promoting the aggressive and metastatic phenotypes. As MUC1 is a STAT3 target gene, STAT3 plays a major role in regulating MUC1-C expression. In this study, we report an alternative mechanism by which integrin-linked kinase (ILK) post-transcriptionally modulates the expression of MUC1-C by maintaining its protein stability in pancreatic cancer cells. We found that ILK acts in concert with STAT3 to facilitate IL-6-mediated upregulation of MUC1-C; ILK depletion was equally effective as STAT3 depletion in abolishing IL-6-induced MUC1-C overexpression without disturbing the phosphorylation or cellular distribution of STAT3. Conversely, ectopic expression of constitutively active ILK increased MUC1-C expression, though this increase was not noted with kinase-dead ILK. This finding suggests the requirement of the kinase activity of ILK in regulating MUC1-C stability, which was confirmed by using the ILK kinase inhibitor T315. Furthermore, our data suggest the involvement of protein kinase C (PKC)δ in mediating the suppressive effect of ILK inhibition on MUC1-C repression. For example, co-immunoprecipitation analysis indicated that ILK depletion-mediated MUC1-C phosphorylation was accompanied by increased phosphorylation of PKCδ at the activation loop Thr-507 and increased binding of PKCδ to MUC1-C. Conversely, ILK overexpression resulted in decreased PKCδ phosphorylation. From a mechanistic perspective, the present finding, together with our recent report that ILK controls the expression of oncogenic KRAS through a regulatory loop, underscores the pivotal role of ILK in promoting pancreatic cancer progression.
Mucin 1 (MUC1), a heterodimeric transmembrane glycoprotein, is one of the mucin family members that form protective mucous barriers on epithelial surfaces.1 The MUC1 gene encodes a single polypeptide chain that is auto-proteolytically cleaved to generate two subunits, the N-terminal subunit (MUC1-N) and the C-terminal subunit (MUC1-C), which form a stable complex.2, 3 Dysregulated expression of MUC1 has been associated with the progression of many types of epithelial tumors due to its myriad oncogenic functions. In addition to its protective and lubricative functions for the underlying epithelia, MUC1 also regulates diverse cellular functions that promote the aggressive and metastatic phenotypes of cancer cells through an intricate interplay of the MUC1-C subunit with various signaling effectors at different subcellular locales.3, 4, 5, 6, 7 At the cell membrane, MUC1-C interacts with epidermal growth factor receptor and other receptor tyrosine kinases, leading to the activation of downstream signaling cascades.3, 6, 8 Moreover, cytoplasmic MUC1-C can be translocalized into the nucleus and mitochondria via distinct mechanisms, where it activates multiple nuclear signaling pathways and blocks activation of the intrinsic apoptotic pathway, respectively.3, 5, 6 Particularly noteworthy is the role of MUC1-C as a regulator of cell metabolism, which confers resistance to hypoxia and metabolic stress upon cancer cells.9 Consequently, MUC1 overexpression in the mammary gland results in breast tumorigenesis in the MMTV–MUC1 transgenic model.10 Taken together, MUC1-C represents a clinically relevant target for cancer therapy,5, 6, 8 with the proof of concept provided by the in vivo efficacy of different peptide inhibitors of MUC1-C heterodimerization, including PMIP11 and GO-201/203,12, 13, 14 in suppressing xenograft tumor growth in different animal models. Moreover, GO-203-2c is currently undergoing phase I evaluation in patients with acute myeloid leukemia (https://clinicaltrials.gov/ct2/show/NCT02204085).
There is evidence that cancer cells adopt multiple strategies, at the transcriptional, post-transcriptional and epigenetic levels, to regulate MUC1-C expression to gain growth advantage.5, 15, 16, 17, 18, 19 The mucin gene MUC1 was reported to be a target gene of STAT3 in various cancer cell lines.20, 21 Especially noteworthy is a reported autoinductive loop between MUC1-C and STAT3 in breast cancer cells, in which MUC1-C facilitates JAK1-mediated STAT3 activation through complex formation, leading to activation of MUC1 gene.22 Furthermore, evidence suggests that peroxisome proliferator-activated receptor (PPAR)γ has a dichotomous role in regulating MUC1 expression in a cell type/context-specific manner. For example, while liganded PPARγ stimulates MUC1 induction in murine trophoblasts,23 it was reported to antagonize progesterone-mediated MUC1 expression in human uterine epithelial cell lines and T47D breast cancer cell lines.24 Moreover, PPARγ acts as an E3 ligase to facilitate MUC1-C degradation in HT-29 and MCF-7 cells independent of its transcriptional activity.25 In addition to gene amplification and transcriptional activation,6 breast cancer cells might also increase MUC1-C expression by abrogating the expression of miR-125b or miR-145, which suppressed the translation of MUC1 by binding to the MUC1 3′UTR.17, 26
Integrin-linked kinase (ILK) is a serine/threonine kinase that exhibits a multitude of oncogenic functions in promoting carcinogenesis and tumor progression in different cancer types.27, 28, 29 For example, in pancreatic cancer, ILK regulates tumor growth via the activation of the Akt and STAT3 signaling pathways,30 and plays a key role in IL-1β-induced enhancement of adhesion and invasion through a p38 MAP kinase-dependent pathway.31 More recently, our laboratory demonstrated a KRAS–ILK regulatory loop that links ILK to the regulation of oncogenic KRAS expression.32 In this study, we report an alternative mechanism for ILK to post-transcriptionally regulate the expression of MUC1-C by maintaining MUC1-C protein stability in pancreatic cancer cells, which, in conjunction with STAT3, is responsible for IL-6-mediated upregulation of MUC1-C. Specifically, ILK negatively regulated protein kinase C (PKC)δ, which facilitated the phosphorylation and subsequent proteasomal degradation of MUC1-C. In consequence, MUC1-C expression could be suppressed by genetic depletion or pharmacological inhibition of ILK through protein destabilization. From a mechanistic perspective, the unique ability of ILK to regulate MUC1-C stability, in conjunction with STAT3-activated MUC1 gene expression,22 upregulates MUC1-C and enables pancreatic cancer cells to interact with the tumor microenvironment to promote an aggressive phenotype.
ILK mediated the effect of IL-6 on MUC1-C overexpression concurrently with STAT3 activation
We measured MUC1-C expression in normal pancreatic cells (NPCs) versus different pancreatic cancer cell lines by western blot analysis. While NPCs, BxPC-3, Panc-1 and MiaPaCa2 cells lacked appreciable MUC1-C expression, AsPC-1 and SW1990 cells exhibited low and high abundance of MUC1-C, respectively (Figure 1a). Consistent with the reported effect of IL-6 on MUC1 overexpression in breast and lung cancer cells,22, 33 exposure of AsPC-1 cells to IL-6 led to parallel increases in STAT3 phosphorylation and the expression of MUC1-C, and, to a lesser extent, ILK (Figure 1b). The ability of IL-6 to stimulate MUC1-C expression was confirmed by the stable expression of IL-6 in AsPC-1 (AsPC-1IL-6) cells (Figure 1b, right panel) and in IL-6-treated SW1990 cells (Figure 1c, left). This phenomenon, however, was not noted in MUC1-deficient Panc-1 cells (Figure 1c, right),
As MUC1 is a STAT3 target gene,20, 21, 22, 33 it follows that STAT3 activation played a crucial role in regulating MUC1-C expression in AsPC-1 cells. STAT3 depletion by two different shRNAs (#886 and #887) was effective in reducing the expression of endogenous MUC1-C as well as in blocking IL-6-induced MUC1-C upregulation (Figure 1d). In parallel, we also examined the effect of shRNA-mediated ILK knockdown on MUC1 expression in AsPC-1 cells treated with exogenous IL-6 or stably expressing IL-6. It is noteworthy that ILK depletion was equally as effective as STAT3 depletion in abolishing IL-6-induced MUC1-C overexpression (Figure 2a). Similarly, shRNA-mediated knockdown of E2F1, a transcription factor that regulates ILK gene expression,32, 34 led to parallel decreases in MUC1-C levels in AsPC-1 cells (Figure 2b). In order to rule out the possibility that the inhibitory effect of ILK knockdown on MUC1-C expression might be associated with its ability to interfere with STAT3 signaling, we fractionated cellular and nuclear fractions to determine ILK knockdown affect the phosphorylation and/or cellular distribution of STAT3 in response to IL-6. However, this ILK depletion did not cause appreciable changes in the phosphorylation or cellular distribution of STAT3 in IL-6-treated AsPC-1 cells (Figure 2c), indicating that this suppressive effect was attributable to the cooperative interplay between ILK and STAT3. Moreover, although silencing of ILK caused a sharp decrease in MUC1-C abundance, the mRNA expression of MUC1 remained unaltered (Figure 2d). Furthermore, ILK knockdown in untreated AsPC-1 and SW1990 cells caused downregulation of endogenous MUC1-C expression without affecting MUC1 mRNA levels (Figure 2e). We also found ILK knockdown to have the same effect on MUC1-C expression in two other cancer cell lines, including DU-145 prostate cancer and MDA-MB-231 breast cancer cells (Supplementary Figure S1), revealing that the suppressive effect of ILK depletion on MUC1-C expression was not a cell line-specific phenomenon. Together, these findings demonstrated the unique ability of ILK to regulate MUC1-C expression independently of MUC1 gene expression.
The mechanistic link between ILK and MUC1-C expression was further confirmed by the ability of ectopically expressed constitutively active ILK to increase MUC1-C expression in AsPC-1 cells (Figure 3a, left). This upregulation, however, did not occur when the kinase-dead form of ILK was overexpressed (right), suggesting that the kinase activity of ILK was required to mediate the effect on MUC1-C expression. Pursuant to this finding, we used an ILK kinase inhibitor, T315,32, 35 as a proof of concept to verify the functional role of ILK. Consistent with the consequences of ILK depletion, exposure of AsPC-1, AsPC-1IL-6 and SW1990 cells to T315 suppressed the expression of endogenous MUC1-C and inhibited IL-6-induced MUC1-C overexpression (Figure 3b). Furthermore, T315 (2 μM) was effective in abrogating the effect of ILK overexpression on MUC1-C expression (Figure 3c). Quantitative real-time PCR (qRT-PCR) analysis indicated that MUC1 mRNA expression levels remained largely unaltered by T315 in AsPC-1 and SW1990 cells, with the exception of T315 at 3 μM in AsPC-1 cells (Figure 3d), which might be attributed to extensive cell death. Nevertheless, overexpression of ILK-CA failed to increase MUC1-C levels in STAT3-depleted AsPC-1 cells, suggesting that ILK acted downstream of STAT3 in regulating MUC1-C expression (Figure 3e).
In addition to IL-6, hypoxia also induces MUC1-C accumulation in pancreatic cancer cells, in turn driving hypoxia-driven angiogenesis.36 Consistent with this report, subjecting AsPC-1 cells to hypoxic conditions led to MUC1-C upregulation in a time-dependent manner, which could be reversed to the basal level by T315 treatment (Supplementary Figure S2).
ILK inhibition promotes ubiquitin-dependent MUC1-C degradation
On the basis of the qRT-PCR evidence that genetic knockdown or pharmacological inhibition of ILK did not alter MUC1 mRNA levels, we hypothesized that the effect of ILK inhibition on MUC1-C downregulation was attributable to proteasomal degradation, which was supported by the following studies. First, we used pulse chase assays to analyze the effect of ILK inhibition on MUC1-C protein stability. In the presence of cycloheximide, shRNA-mediated depletion of ILK (Figure 4a, upper) or T315 (lower) promoted the clearance of MUC1-C, relative to the DMSO control, in both AsPC-1 and SW1990 cells. Second, the proteasome inhibitor MG-132 protected AsPC-1 cells against the suppressive effect of T315 on MUC1-C expression (Figure 4b). Third, we used co-immunoprecipitation (Co-IP) analysis to investigate the effect of ILK inhibition on MUC1-C ubiquitination. In AsPC-1 and SW1990 cells ectopically expressing HA-tagged ubiquitin (HA-Ub), the ability of T315 (2 μM) or genetic ILK knockdown to suppress MUC1-C expression was attributable to increased MUC1-C ubiquitination (Figures 4c and d). Together, these data reveal the pivotal role of ILK in the regulation of MUC1-C protein stability.
PKCδ is involved in mediating the ubiquitin-dependent degradation of MUC1-C in response to ILK inhibition
As ubiquitin-dependent protein degradation is preceded by phosphorylation,37 we evaluated the effect of T315 on MUC1-C phosphorylation via Co-IP. As shown, concentration-dependent downregulation of MUC1-C expression was associated with parallel increases in Ser/Thr phosphorylation in both AsPC-1 and SW1990 cells (Figure 5a). Although MUC1-C is known to be phosphorylated by multiple kinases,8 including glycogen synthase kinase (GSK)3β and PKCδ,38, 39 the identity of the kinase responsible for its degradation remained undefined. Thus, we analyzed a panel of kinase inhibitors for the ability to block T315-induced suppression of MUC1-C expression in AsPC-1 cells, including the pan-PKC inhibitor GF-109203X, the casein kinase (CK)2α inhibitor DMAT, the c-Jun N-terminal kinase (JNK) inhibitor SP-600125, the p38 MAP kinase inhibitor SB-203580, the IκB kinase (IKK)α inhibitor Bay-11-7082 and the GSK3β inhibitor SB-216763. It is noteworthy that GF-109203X, when used alone, increased MUC1-C accumulation, and was able to partially protect cells from the suppressive effect of T315, and, to a greater extent, ILK knockdown on MUC1-C expression (Figures 5b and c). In contrast, none of the other kinase inhibitors examined exhibited the ability to rescue cells from T315-mediated MUC1-C downregulation (Figure 5b).
To identify the PKC isozyme responsible for MUC1-C degradation, we selectively depleted individual isozymes (α, β, γ, δ and ɛ) with two different shRNAs each and assessed the effects on T315-facilitated suppression of MUC1-C expression in AsPC-1 cells. Among these five isozymes, only knockdown of PKCδ resulted in the desired protective effect on MUC1-C repression, while silencing of the other isozymes had no significant appreciable protection (Figure 6a). The intermediary role of PKCδ in mediating this cellular response was further confirmed by the following experiments in AsPC-1 cells. First, Co-IP analysis revealed that ILK knockdown-mediated phosphorylation of MUC1-C was accompanied by a parallel increase in the binding of PKCδ to MUC1-C. This increased binding, however, was not noted with the negative control PKCα (Figure 6b). Second, shRNA-mediated depletion of ILK led to increased phosphorylation of PKCδ at the activation loop Thr-507, while PKCα phosphorylation remained unaltered (Figure 6c, left). Conversely, overexpression of ILK in AsPC-1 cells resulted in the reversal of the above changes in MUC1-C expression and Thr-507-PKCδ phosphorylation (Figure 6c, right). Taken together, these data suggest that PKCδ is regulated by ILK inhibition, as well as involved in ILK-mediated ubiquitin-dependent MUC1-C degradation.
Pursuant to a recent report that PPARγ acts as an E3 ligase responsible for MUC1-C degradation independent of its transcriptional activity in HT-29 and MCF-7 cells,25 we investigated the potential involvement of PPARγ in T315-induced MUC1-C repression by examining whether siRNA-mediated knockdown of PPARγ could protect cells from this drug-induced MUC1-C degradation. However, silencing of PPARγ alone caused suppression of MUC1-C expression, and, together with T315, completely depleted MUC1-C in AsPC-1 and SW1990 cells (Figure 7a). Together, these data argued against the involvement of PPARγ as an E3 ligase in facilitating T315-mediated MUC1-C degradation in these pancreatic cancer cells.
To identify the E3 ligase responsible for ILK inhibition-induced MUC1-C degradation, we turned our attention to Fbw7 (F-box and WD repeat domain-containing 7; aka, Fbxw7) and β-TrCP in light of their tumor-suppressive activities in facilitating the degradation of oncogenic proteins.40 Accordingly, we analyzed the effects on MUC1-C expression when we depleted Fbw7 in SW1990 cells and β-TrCP in AsPC-1 cells, considering the endogenous levels of these E3 ligases in these two cell lines. In principle, silencing of the responsible E3 ligase should lead to the accumulation of MUC1-C. As shown, a dose-dependent reduction in Fbw7 expression caused a parallel decrease in MUC1-C levels (Figure 7b), while silencing of β-TrCP not only substantially increased the expression of MUC1-C, but also protected AsPC-1 cells from ILK depletion-induced downregulation of MUC1-C expression. Together, these data suggest the potential involvement of β-TrCP in mediating the ubiquitin-dependent degradation of MUC1-C, which warrants further investigation.
In vivo mechanistic validation
To confirm our findings of the functional role of ILK in mediating PKCδ-dependent MUC1-C degradation in vivo, we examined the expression levels of relevant biomarkers in T315-treated AsPC-1 tumors after 21 days of treatment. These tumor samples were previously prepared in our recent study of the KRAS–ILK signaling loop, in which daily oral administration of T315 at 50 mg/kg inhibited AsPC-1 xenograft tumor growth by 51% (described in the Supplementary Figure S2 of cited reference;32 http://www.nature.com/onc/journal/v35/n30/extref/onc2015458x1.pdf). Consistent with the in vitro finding, T315 significantly downregulated ILK and MUC1-C expression and increased PKCδ phosphorylation in AsPC-1 tumors in nude mice (P<0.05; Figure 8).
Substantial evidence indicates that MUC1-C signaling is upregulated in the course of tumor progression to promote an aggressive phenotype, in part, through crosstalk with the tumor microenvironment.5, 6, 8 For example, a number of stress signals, including IL-6 and hypoxia, have been reported to induce the accumulation of MUC1-C to drive epithelial-mesenchymal transition (EMT) and angiogenesis.22, 36 Multiple mechanisms at different molecular levels have been reported to regulate MUC1-C overexpression,5, 15, 16, 17, 18, 19 among which the MUC1-C–STAT3 autoinductive loop in breast cancer cells is especially noteworthy.22 Here we report a post-transcriptional mechanism, in which ILK acts by blocking PKCδ-mediated protein degradation of MUC1-C. From a mechanistic perspective, the cooperative interplay between STAT3 and ILK would facilitate an immediate cellular response to IL-6 and other stress signals to upregulate MUC1-C expression at both transcriptional and post-transcriptional levels. As overexpression of ILK could not rescue the effect of STAT3 depletion on MUC1-C expression, it is likely that ILK acts downstream of STAT3 in MUC1-C regulation. Nevertheless, genetic knockdown or pharmacological inhibition of ILK caused depleted MUC1-C expression in IL-6-treated pancreatic cancer cells, indicating that ILK is required to sustain STAT3-induced MUC1 upregulation by maintaining its stability.
Moreover, in light of the ability of ILK to regulate oncogenic KRAS signaling,32 the present study also provides a mechanistic link between KRAS and MUC1-C. As MUC1-C has been reported to confer KRAS independence in mutant KRAS lung cancer cells,41 it warrants investigation whether targeting ILK can mitigate the effect of MUC1-C overexpression on KRAS independence.
Evidence suggests that T315-mediated MUC1-C degradation was facilitated by PKCδ-mediated phosphorylation (Figure 6). This finding is consistent with the report that PKCδ binds and phosphorylates MUC1-C on Thr-41 at the TDRSPY motif, which attenuates the interaction between MUC1-C and β-catenin.39 As PKCδ is activated in response to oxidative or genotoxic stress to trigger apoptotic responses,42, 43, 44 we hypothesize that activation of PKCδ by genetic depletion of ILK or T315 was attributable to reactive oxygen species (ROS) production and/or DNA damage, which is currently under investigation.
In contrast to the reported function of PPARγ as the E3 ligase responsible for MUC1-C degradation independent of its transcriptional activity in HT-29 and MCF-7 cells,25 our data refute this mechanistic link, as PPARγ depletion reduced endogenous MUC1-C expression and could not protect cells from T315-induced depletion of MUC1-C. This discrepancy might be attributable to differences in cell lines and cellular contexts between these two studies. In the present study, we obtained evidence that β-TrCP might be involved in ILK depletion-induced MUC1-C degradation. This has prompted further confirmation and is under investigation.
In summary, because ILK is activated in response to IL-6 and other environmental signals,34, 45 the unique ability of ILK to regulate MUC1-C stability, in conjunction with STAT3-activated MUC1 gene expression,22 enables pancreatic cancer cells to interact with stress signals in the tumor microenvironment, such as IL-6 and hypoxia. The interactions promote an aggressive phenotype, in part through MUC1-C upregulation. From a mechanistic perspective, the present finding, together with our recent report that ILK controls the expression of oncogenic KRAS through a regulatory loop,32 underscores the pivotal role of ILK in promoting pancreatic cancer progression.
Materials and methods
Cell line, culture and reagents
Non-malignant human primary pancreatic cells (NPC) were purchased from Applied Biological Materials (Richmond, BC, Canada) and cultured in Prigrow I medium. AsPC-1, BxPC-3, Panc-1, MiaPaCa2 and SW1990 pancreatic cancer cells, DU-145 prostate cancer cells, and MDA-MB-231 breast cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA). AsPC-1, BxPC-3, Panc-1, SW1990 and DU-145 cells were cultured in RPMI 1640 medium, and MiaPaCa2 and MDA-MB-231 cells were cultured in DMEM medium, supplemented with penicillin–streptomycin and 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Cells were cultured at 37 °C in a humidified incubator containing 5% CO2. In hypoxia incubation, cells were cultured in hypoxia chamber (Proox 110, BioSpherix, Parish, NY, USA), flushed with 1% O2, 5% CO2 and 94% N2 at 37°C for the indicated time. Cells were recently authenticated by STR profiling and tested to confirm mycoplasma free. The ILK inhibitor T315 was synthesized in our laboratory as described previously.35 MG-132, SP-600125, SB-203580 and SB-216763 were purchased from Sigma-Aldrich (St Louis, MO, USA), and Bay-11-7082, cycloheximide and GF-109203X were from Calbiochem (San Diego, CA, USA). Antibodies for various proteins were from the following sources: ILK, Flag, STAT3, p-Tyr-705 STAT3, CREB, α-tubulin, Cell Signaling Technology (Danvers, MA, USA); MUC1-C, β-TrCP, Thermo Fisher Scientific (Fremont, CA, USA); β-actin, MP Biomedicals (Irvine, CA, USA); p-Ser/Thr, Fbw7, Abcam, (Cambridge, MA, USA); ubiquitin, PKCα, p-Ser-657 PKCα, PKCβII, PKCδ, p-Thr-507-PKCδ, PKCɛ, PKCγ, PPARγ, Santa Cruz Biologicals (Santa Cruz, CA, USA); rabbit anti-mouse IgG-HRP conjugates, goat anti-rabbit IgG-HRP conjugates, goat anti-Armenian hamster HRP conjugates, Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Specific catalog numbers for each antibody are listed in Supplementary Table S1.
AsPC-1IL-6 stable clone selection
AsPC-1 cells were seeded in a 6-cm dish and transiently transfected with the pCMV-IL6 plasmid. After 2 days, cells were expanded into ten 10-cm dishes and incubated with fresh culture medium containing G418 until colonies grew. Each single colony was then trypsinized using a cloning cylinder and expanded. IL-6 secretion into culture medium by cell colonies was analyzed by the IL-6 DuoSet ELISA kit (R&D, Minneapolis, MN, USA) according to the manufacturer’s instructions. One clone that produced the optimal amount of IL-6 in culture medium (550 ng/ml versus nil for parental AsPC-1 cells), designated as AsPC-1IL-6, was used in this study.
Transient transfection and immunoblotting
Cells were transfected with plasmids or siRNAs using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. pCMV-IL6, Flag-tagged ILK-WT and GFP-tagged ILK (ILK-CA and ILK-KD) plasmids were generated as previously described.32, 34 Other plasmids, shRNA and siRNA used in this study and their sources were: pcDNA3.1, Addgene (Cambridge, MA, USA); ILK siRNA (#6202), Cell Signaling Technology (Beverly, MA, USA); E2F1 shRNA, PPARγ siRNA, Santa Cruz Biologicals; Fbw7 siRNA and β-TrCP siRNA, OriGene Technologies Inc. (Rockville, MD, USA). Immunoblotting and densitometric analysis were performed as previously described.34
Lentivirus preparation and transfection
Lentivirial plasmids were cotransfected with the third Generation Packaging Systems (pMDLg/pRRE, #12251; pRSV-Rev, #12253; pMD2.G #12259) (Addgene) in 293T cells following a standard calcium phosphate transfection procedure. Viral particles were collected for transfection of target cells, followed by puromycin selection for 1 week to generate stable cell lines. The following lentiviral plasmids were obtained from Academia Sinica (Taipei, Taiwan): pLAS.Void (negative control), shILK (#0968), shSTAT3 (886, 887), shPKCα (#3511, #6909), shPKCβ1 (#3117, #5381), shPKCδ (#1180, #2640), shPKCɛ (#0844, #0848) and shPKCγ (#0693, #2326).
The following buffers were used for nuclear fractionation: harvest buffer (10 mM, 50 mM NaCl, 0.5 M sucrose, 0.1 mM EDTA, 0.5% Triton X-100); buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA); buffer C (10 mM HEPES pH 7.9, 500 nM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP-40). Immediately before use, the following was added to each buffer: 2 mM sodium orthovanadate, 5 mM NaF, 1 mM sodium pyrophosphate, 2.5 mM glycerol phosphate, 1 mM DTT, 1 mM PMSF and protease inhibitor. After the indicated treatment, cells were collected and resuspended in cold harvest buffer with 5 min incubation on ice. Cells were centrifuged at 3000 rpm for 10 min and supernatant were collected and centrifuged at 14 000 rpm for 15 min. The supernatants were collected as cytoplasmic proteins and membrane proteins. The pellet was washed using buffer A and resuspended in buffer C. The resuspended pellet was vortexed at high speed for 30 s and incubated on ice for 10 min three times. After centrifugation at 13 000 rpm for 15 min, the supernatant was collected as nuclear proteins.
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse-transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad; Hercules, CA, USA). For qRT-PCR, cDNA was amplified in iQ SYBR Green Supermix (Bio-Rad) and detected with the Bio-Rad CFX96 RT-PCR detection system. Relative gene expression was normalized to GAPDH and calculated by using the 2(−ΔΔCT) method. The primer sequences were: MUC1, forward: 5′-IndexTermACCTACCATCCTATGAGCGAG-3′, reverse: 5′-IndexTermGGTTTGTGTAAGAGAGGCTGC-3′; GAPDH: forward: 5′-IndexTermAGGGGTCTACATGGCAACTG-3′, reverse: 5′-IndexTermCGACCACTTTGTCAAGCTCA-3′.
Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100) containing phosphatase and protease inhibitor mixture on ice for 30 min. After centrifugation at 13 000 g for 10 min, one-tenth the volume of the supernatant was stored at 4 °C for use as input, and the remainder was incubated with 20 μl protein A/G-sepharose beads at 4 °C for 1 h to eliminate nonspecific binding. Protein A/G beads were then removed by centrifugation and the supernatants were incubated with primary antibodies at 4 °C overnight with rocking followed by incubating with 20 μl protein A/G-sepharose beads at 4 °C for 2 h. The immunocomplexes were washed with lysis buffer, resuspended in 2 × sample buffer, and then subjected to immunostaining.
Each experiment was performed at least three times. Student’s t-test was performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA) to compare the mean of each group with that of the control group in experiments. P-values less than 0.05 were considered significant (*P<0.05, **P<0.01, ***P<0.001).
Hanisch FG, Muller S . MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000; 10: 439–449.
Kufe DW . Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874–885.
Nath S, Mukherjee P . MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20: 332–342.
Hattrup CL, Gendler SJ . Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008; 70: 431–457.
Horm TM, Schroeder JA . MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr 2013; 7: 187–198.
Kufe DW . MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013; 32: 1073–1081.
Singh PK, Hollingsworth MA . Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006; 16: 467–476.
Kufe DW . Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009; 8: 1197–1203.
Mehla K, Singh PK . MUC1: a novel metabolic master regulator. Biochim Biophys Acta 2014; 1845: 126–135.
Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739–5747.
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009; 15: 100–109.
Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20: 5423–5434.
Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 5133–5141.
Rajabi H, Ahmad R, Jin C, Joshi MD, Guha M, Alam M et al. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate 2012; 72: 1659–1668.
Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D . Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 2013; 32: 2179–2188.
Lagow EL, Carson DD . Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem 2002; 86: 759–772.
Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D . Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer 2010; 1: 62–68.
Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 2008; 68: 2708–2716.
Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I . Analysis of the promoter of the MUC1 gene overexpressed in breast cancer. FEBS Lett 1999; 461: 189–195.
Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J . A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001; 276: 6191–6199.
Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE . Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol 2004; 24: 9390–9400.
Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 2011; 4: ra9.
Shalom-Barak T, Nicholas JM, Wang Y, Zhang X, Ong ES, Young TH et al. Peroxisome proliferator-activated receptor gamma controls Muc1 transcription in trophoblasts. Mol Cell Biol 2004; 24: 10661–10669.
Wang P, Dharmaraj N, Brayman MJ, Carson DD . Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression. Mol Endocrinol 2010; 24: 1368–1379.
Hou Y, Gao J, Xu H, Xu Y, Zhang Z, Xu Q et al. PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene 2014; 33: 5619–5625.
Sachdeva M, Mo YY . MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70: 378–387.
Hannigan G, Troussard AA, Dedhar S . Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51–63.
Hannigan GE, McDonald PC, Walsh MP, Dedhar S . Integrin-linked kinase: not so 'pseudo' after all. Oncogene 2011; 30: 4375–4385.
McDonald PC, Fielding AB, Dedhar S . Integrin-linked kinase—essential roles in physiology and cancer biology. J Cell Sci 2008; 121: 3121–3132.
Yau CY, Wheeler JJ, Sutton KL, Hedley DW . Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65: 1497–1504.
Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 2006; 25: 3237–3246.
Chu PC, Yang MC, Kulp SK, Salunke SB, Himmel LE, Fang CS et al. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. Oncogene 2016; 35: 3897–3908.
Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY . Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line. Cell Immunol 2009; 256: 19–26.
Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ et al. Function of integrin-linked kinase in modulating the stemness of IL-6-abundant breast cancer cells by regulating gamma-secretase-mediated notch1 activation in caveolae. Neoplasia 2015; 17: 497–508.
Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem 2011; 54: 6364–6374.
Kitamoto S, Yokoyama S, Higashi M, Yamada N, Takao S, Yonezawa S . MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene 2013; 32: 4614–4621.
Nakayama KI, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369–381.
Li Y, Bharti A, Chen D, Gong J, Kufe D . Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998; 18: 7216–7224.
Ren J, Li Y, Kufe D . Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 2002; 277: 17616–17622.
Lau AW, Fukushima H, Wei W . The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci 2012; 17: 2197–2212.
Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D . MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 2014; 5: 8893–8905.
Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS . Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology 2011; 53: 148–159.
Liu H, Lu ZG, Miki Y, Yoshida K . Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 2007; 27: 8480–8491.
Yamaguchi T, Miki Y, Yoshida K . Protein kinase C delta activates IkappaB-kinase alpha to induce the p53 tumor suppressor in response to oxidative stress. Cell Signal 2007; 19: 2088–2097.
Chou CC, Chuang HC, Salunke SB, Kulp SK, Chen CS . A novel HIF-1alpha-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1alpha expression and epithelial-mesenchymal transition in cancer cells. Oncotarget 2015; 6: 8271–8285.
This work was supported by Grant # MOST 105-2321-B-001-064 from the Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan, the Lucius A Wing Endowed Chair Fund at The Ohio State University Medical Center (CSC) and a predoctoral fellowship from the Graduate Student Study Abroad Program, National Science Council, Taiwan (H-LH).
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Oncogenesis website
About this article
Cite this article
Huang, HL., Wu, HY., Chu, PC. et al. Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells. Oncogenesis 6, e359 (2017). https://doi.org/10.1038/oncsis.2017.61
Mucins in pancreatic cancer: A well‐established but promising family for diagnosis, prognosis and therapy
Journal of Cellular and Molecular Medicine (2020)
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
Medicinal Research Reviews (2020)
Substratum stiffness tunes proliferation downstream of Wnt3a in part by regulating integrin-linked kinase and frizzled-1
Journal of Cell Science (2018)
LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1
Biochemical and Biophysical Research Communications (2018)